These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 31977390)

  • 21. Enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
    Rodriguez-Vida A; Galazi M; Rudman S; Chowdhury S; Sternberg CN
    Drug Des Devel Ther; 2015; 9():3325-39. PubMed ID: 26170619
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Management of enzalutamide, a new hormonal therapy].
    Beuzeboc P; Benderra MA; de La Motte Rouge T
    Bull Cancer; 2014 Jan; 101(1):107-12. PubMed ID: 24491670
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Next Generation of Androgen Deprivation Therapy Combined With Radiotherapy for N0 M0 Prostate Cancer.
    Barata P; Layton J; Lewis B; Sartor O
    Cancer J; 2020; 26(1):21-28. PubMed ID: 31977381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. PROACTA: a survey on the actual attitude of the Italian radiation oncologists in the management and prescription of hormonal therapy in prostate cancer patients.
    Fersino S; Borghesi S; Jereczek-Fossa BA; Arcangeli S; Mortellaro G; Magrini SM; Alongi F;
    Radiol Med; 2021 Mar; 126(3):460-465. PubMed ID: 32852750
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Overview of Systemic Therapy Augmenting Management of High-risk Localized Prostate Cancer.
    Vicier C; Feng FY; Fizazi K
    Eur Urol Focus; 2019 Mar; 5(2):168-170. PubMed ID: 30745118
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer.
    Aguiar PN; Tan PS; Simko S; Barreto CMN; Gutierres BS; Giglio AD; Lopes GL
    Einstein (Sao Paulo); 2019 Mar; 17(2):eGS4414. PubMed ID: 30843996
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.
    McNamara M; Sweeney C; Antonarakis ES; Armstrong AJ
    Prostate Cancer Prostatic Dis; 2018 Sep; 21(3):306-318. PubMed ID: 29263421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Metastatic Castration-resistant Prostate Cancer: Piling Up the Benefits of Chemotherapy.
    Tombal B
    Eur Urol; 2015 Aug; 68(2):236-7. PubMed ID: 24908474
    [No Abstract]   [Full Text] [Related]  

  • 29. [2017 ASCO: Complete androgen blockade strikes back].
    Penel N
    Bull Cancer; 2017; 104(7-8):599-601. PubMed ID: 28688745
    [No Abstract]   [Full Text] [Related]  

  • 30. The effect of statins on advanced prostate cancer patients with androgen deprivation therapy or abiraterone/enzalutamide: A systematic review and meta-analysis.
    Yang H; Pang L; Hu X; Wang W; Xu B; Zhang X; Liu L
    J Clin Pharm Ther; 2020 Jun; 45(3):488-495. PubMed ID: 31951037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fatigue, quality of life and metabolic changes in men treated with first-line enzalutamide versus abiraterone plus prednisolone for metastatic castration-resistant prostate cancer (HEAT): a randomised trial protocol.
    Kvorning Ternov K; Sønksen J; Fode M; Lindberg H; Kistorp CM; Bisbjerg R; Palapattu G; Østergren PB
    BMJ Open; 2019 Sep; 9(9):e030218. PubMed ID: 31511288
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Hormone therapy in prostate cancer; a pharmacotherapeutic challenge].
    Westdorp H; Benoist GE; Schers HJ; van Erp PH; Gerritsen WR; Mulders PF; Kramers C
    Ned Tijdschr Geneeskd; 2015; 159():A9250. PubMed ID: 26246066
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
    Sweeney CJ; Martin AJ; Stockler MR; Begbie S; Chi KN; Chowdhury S; Coskinas X; Frydenberg M; Hague WE; Horvath LG; Joshua AM; Lawrence NJ; Marx GM; McCaffrey J; McDermott R; McJannett M; North SA; Parnis F; Parulekar W; Pook DW; Reaume MN; Sandhu SK; Tan A; Tan TH; Thomson A; Tu E; Vera-Badillo F; Williams SG; Yip S; Zhang AY; Zielinski RR; Davis ID;
    Eur Urol; 2021 Sep; 80(3):275-279. PubMed ID: 34030924
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effect of Time to Castration Resistance on Outcomes With Abiraterone and Enzalutamide in Metastatic Prostate Cancer.
    Hung J; Taylor AR; Divine GW; Hafron JM; Hwang C
    Clin Genitourin Cancer; 2016 Oct; 14(5):381-388. PubMed ID: 27157640
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Are There Still Patients with Metastatic Hormone-sensitive Prostate Cancer Who Should Be Treated with Androgen Deprivation Monotherapy?
    Kretschmer A; Todenhöfer T
    Eur Urol Focus; 2019 Mar; 5(2):114-116. PubMed ID: 30482584
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is There a Benefit of Addition Docetaxel, Abiraterone, Celecoxib, or Zoledronic Acid in Initial Treatments for Patients Older Than 70 Years With Hormone-sensitive Advanced Prostate Cancer? A Meta-analysis.
    Landre T; Guetz GD; Chouahnia K; Fossey-Diaz V; Taleb C; Culine S
    Clin Genitourin Cancer; 2019 Aug; 17(4):e806-e813. PubMed ID: 31227430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment strategies for advanced prostate cancer].
    Küronya Z; Bíró K; Géczi L; Németh H
    Magy Onkol; 2015 Sep; 59(3):229-40. PubMed ID: 26339912
    [TBL] [Abstract][Full Text] [Related]  

  • 38. First-line management of metastatic castrate-resistant prostate cancer patients: Audit of real-life practices.
    Turpin A; Pasquier D; Massard C; Berdah JF; Culine S; Penel N
    Bull Cancer; 2017 Jun; 104(6):552-558. PubMed ID: 28390646
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world outcomes in patients with metastatic castration-resistant prostate cancer receiving second-line chemotherapy versus an alternative androgen receptor-targeted agent (ARTA) following early progression on a first-line ARTA in a US community oncology setting.
    Oh WK; Cheng WY; Miao R; Vekeman F; Gauthier-Loiselle M; Duh MS; Drea E; Szatrowski TP
    Urol Oncol; 2018 Nov; 36(11):500.e1-500.e9. PubMed ID: 30201382
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapies for castration-resistant prostate cancer in a new era: The indication of vintage hormonal therapy, chemotherapy and the new medicines.
    Mizokami A; Kadono Y; Kitagawa Y; Izumi K; Konaka H
    Int J Urol; 2017 Aug; 24(8):566-572. PubMed ID: 28577511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.